The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Immunai will generate a publicly accessible multi-omic dataset for a Parker Institute cohort of over 1,000 cancer patients.

Small-cell lung cancer (SCLC) is one of the most aggressive and deadly types of cancer, often linked to smoking. Although it ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

University of the Philippines MANILA, Philippines — A group of scientists from the University of the Philippines (UP) Diliman ...